An Open-label, Non-randomized, Single-center Study, Evaluating the Imaging Characteristics of XTR006 Injection in Non-cognitively Impaired Subjects, MCI Due to Alzheimer Disease (AD), and Mild to Moderate AD Subjects
Latest Information Update: 09 May 2024
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Mild cognitive impairment
- Focus Diagnostic use
- Sponsors Sinotau Pharmaceuticals
Most Recent Events
- 01 May 2024 Status changed from recruiting to completed.
- 07 Dec 2023 New trial record